All News

Since my diagnosis with multiple myeloma, I try to keep inspired to keep moving forward despite the challenges.

Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.

Adcetris plus Revlimid/Rituxan significantly improved outcomes versus Revlimid/Rituxan alone in relapsed/refractory lymphoma.

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer.

With pivotal trial results and an approval from the FDA, the landscape is changing for patients with small cell lung cancer.

A patient with metastatic breast cancer confronts financial toxicity and finds a little glimmer of hope through donating cancer drugs.

Surgery for gynecologic cancers is a common form of treatment, but each surgical approach has its advantages and disadvantages for patients.

Researchers have compared Xtandi and Zytiga head-to-head in the treatment of metastatic castration-resistant prostate cancer.

After being diagnosed with a type of gynecologic cancer, it is essential for patients to understand the molecular makeup of their disease.

Through journaling and connecting with my faith, I was able to embrace everything I was thinking and feeling during colon cancer.

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.

The recent FDA approval of Lazcluze plus Rybrevant for EGFR-mutant non-small cell lung cancer is a “big deal” for patients, an oncologist said.

The novel glioblastoma treatment, APTN-101, had its new drug application accepted by the FDA.

I wrote this poem in honor of my niece who had breast cancer, who was determined to live out the rest of her life giving her loved ones hope and strength.

An extraordinary oncology nurse guided cancer care for a man who was legally blind.

Having myelodysplastic syndromes has taught me to cherish every day and to pursue the things that matter to me, like publishing a book I’ve been writing.

From Roger O’Donnell announcing his aggressive lymphoma diagnosis to “Love Is Blind’s” Shaina Hurley opening up about her cervical cancer while three months pregnant, here’s what’s happening in the oncology space this week.

Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma.

Dr. Partow Kebriaei explains what patients can expect before, during and after an allogeneic stem cell transplant to treat acute lymphoblastic leukemia.

A trial showed no overall survival or progression-free survival benefit from the addition of UV1 to Keytruda in patients with HNSCC.

For patients with MDS, close monitoring by doctors may help determine the appropriate timing to undergo stem cell transplants before the disease worsens.

Having breast cancer has allowed me to truly appreciate and love my husband even more these days.

The Food and Drug Administration granted a fast track designation to IBI363 for patients with unresectable advanced or metastatic melanoma.

I wrote these poems as a testament to strength, courage and resilience for all patients affected by cancer.

A new algorithm has found that combining immune checkpoint inhibitors bolsters immune response among some patients with advanced melanoma.

Patients with oligometastatic pancreatic cancer showed better progression-free survival after receiving metastasis-directed therapy with chemotherapy.

A disease, such as cancer, that affects a person’s physical limitations can catalyze learning to rest, which is something I recently realized.

What information could patients and providers learn from DNA found in a blood sample? An expert sat down with CURE to discuss ctDNA misconceptions.